The market of medicines, also called life science market or biotech market, is one of the largest and fastest growing markets. An ageing population, today’s possibility of developing precision medicine, as well as evolving cell- and gene-therapy, are just some of the drivers for this growth. On top of that, people in emerging markets also want to have access to Western medicine which has fueled sales figures in these territories to a double digit growth.
Although Aescap has a history of investing in smaller private innovative medical companies we have chosen to move to the market of listed companies for several good reasons. First of all, the timing of entering and exiting a listed company can be done on a daily basis which creates the opportunity to time events at an ideal moment both from a company development as well as from a share price point of view. Secondly, listed companies in general are more mature and transparent which decreases the risks involved. Lastly listed innovative medical companies, compared to private ones, are in general further developed in terms of their product pipeline and have easier access to money to finance the company, all of which limits the risks involved.
The two most important reasons to invest in Aescap 2.0 is first of all our outstanding track record in comparison with Exchange Traded Funds (ETFs) and relevant indexes realized by a very experience and hands-on team. Secondly, it is to enable the development of better medical treatments.
Our outperformance is based on an effective strategy. Given the correlation between share prices of biotech companies is only 20%, it makes it one of the best markets for stock picking. We pick and choose 15-20 high growth de-risked companies to invest in, based on a fundamental analysis of innovative medicine companies. Over time, this portfolio of companies changes based on a constant assessment of the portfolio and other companies in our working universe.
Based on a disciplined buy and sell strategy we make use of the typical gloom and doom stories that often appear in our industry. It also prevents us from going along with a bubble. And on top of all of that, we have a regular dialogue with the management of the companies we invest in to see if they are still on the ball and if their vision of the future is a realistic one.
Download our Fact Sheet.
Entry into the fund can take place on a monthly basis in parallel with the monthly determination of the net asset value. An investment in the fund can be initiated by sending the subscription form to SGG Financial Services B.V, via email@example.com. SGG Financial Services B.V is responsible for the fund- and participant administration. In parallel the subscription amount needs to be transferred to the bank account of the Legal Owner: ‘Stichting Aescap 2.0’, bank account IBAN: NL51ABNA0494667826, under the subject ‘Investment in Aescap 2.0’. The minimum subscription amount is €500.000,-. After the completion of the client due diligence and upon receipt of the subscription form and investment amount you will receive a confirmation from SGG Financial Services B.V. Investors will also receive a unique username and password to have excess to your personal investor information on the website of the administrator at all times.
Additional investments need to take place through the same bank account as you have used with the fund before when the initial investment was made. You need to transfer the additional Investment Amount to Stichting Aescap 2.0, IBAN: NL51ABNA0494667826 and state under ‘subject’: ‘Investment in Aescap 2.0’. Your additional investment will be made for the first Business day of the next month.